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Objective No study has reported global disability burden estimates for individual diabetes-
related lower extremity complications (DRLECs). The Global Burden of Diseases (GBD) study 
presents a robust opportunity to address this gap.  
Research Design and Methods GBD 2016 data including prevalence and years lived with 
disability (YLDs) for the DRLECs of diabetic neuropathy, foot ulcer, and amputation with, and 
without prosthesis were used. GBD estimated prevalence using data from systematic reviews 
and DisMod-MR 2.1, a Bayesian meta-regression tool. YLDs were estimated as the product of 
prevalence estimates and disability weights for each DRLEC. We reported global, sex-, age-, 
region- and country-specific estimates for each DRLEC for 1990 and 2016. 
Results In 2016, an estimated 131 million (1.8% of the global population) had DRLECs. An 
estimated 16.8 million YLDs (2.1% global YLDs) were caused by DRLECs, including 12.9 million 
(95% uncertainty interval: 8.30 to 18.8) from neuropathy only, 2.5 million (1.7 to 3.6) foot 
ulcers, 1.1 million (0.7 to 1.4) amputation without prosthesis, and 0.4 million (0.3 to 0.5) 
amputation with prosthesis. Age-standardised YLDs rates of all DRLECs increased by between 
14.6% to 31.0% from 1990 estimates. Male-to-female YLD ratios ranged from 0.96 for 
neuropathy only to 1.93 for foot ulcers. Aged groups 50-69 years accounted for 47.8% of all 
YLDs from DRLECs.  
Conclusions These first ever global estimates suggest DRLECs are a large and growing 
contributor to the disability burden worldwide, and disproportionately affect males and 
middle-to-older aged populations. These findings should facilitate policymakers worldwide to 




The International Diabetes Federation estimated that one in every eleven adults (451 million) 
had diabetes in 2017, and one in ten (693 million) will have diabetes by 2045.(1) People with 
diabetes are at high risk of developing a range of complications, including cardiovascular, 
kidney, eye and lower extremity complications.(2, 3) Arguably the most disabling of these are 
the lower extremity complications of peripheral neuropathy, foot ulceration and 
amputation.(4, 5) 
Diabetes-related lower extremity complications (DRLECs) typically first present as 
neuropathy.(4, 5) Neuropathy is the critical risk factor for developing foot ulceration, and foot 
ulceration the critical risk factor for foot infection and amputation.(4, 5) It is estimated that 
up to 50% of people with diabetes have neuropathy,(6, 7) up to 34% will develop a foot ulcer 
in their lifetime,(5) around 50% of those ulcers will become infected,(8-10) and 20% 
amputated.(5, 10, 11) DRLECs also account for up to 80% of global lower extremity 
amputations, are a leading cause of hospitalisation,(12-14) and result in significant reductions 
in quality of life.(4, 15) Thus, DRLECs appear to cause considerable global disability burden.  
Whilst several narrative reviews have reported basic global epidemiology estimates for some 
DRLECs, (4-6, 16, 17) only one paper has reported a robust global prevalence estimate based 
on systematic reviews.(16) In this meta-analysis, the authors reported a pooled global foot 
ulcer prevalence of 4.6% in the diabetes population and also reported foot ulcer prevalence 
estimates for five geographical regions and 33 countries.(16) Otherwise, no paper has 
systematically reported global, regional or country prevalence estimates for the other 
individual DRLECs, including neuropathy and amputations.  
Additionally, to our knowledge, only our group has reported an estimate of the global 
disability burden of DRLECs.(18) In a brief published letter we used data from the Global 
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Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2015 to report an overall estimate 
for the years lived with disability (YLD) caused by aggregated DLRECs in 2015.(18) YLDs is an 
important population measure of disability burden (or non-fatal health loss) as it enables 
objective comparisons of disability burden of a condition across different populations or for 
different conditions within the same population.(19) YLDs are calculated by multiplying the 
total numbers of people affected by a condition by the average severity of disability for that 
condition (disability weight).(19) However, in that letter we did not report YLD estimates for 
individual DRLECs or estimates by sex, age, region, or country.(18) Thus, robust data on the 
global, regional and country prevalence and disability burden of DRLECs is still not accessible 
to decision makers. GBD presents a unique and robust opportunity to address this gap.  
GBD is a multinational collaborative research project, which systematically integrates all 
available data to produce consistent, transparent and up-to-date estimates on the disability 
and mortality burdens of most diseases and injuries impacting the world.(19-23) Initiated in 
the early 1990s by the World Health Organisation, and since 2010 independently funded by 
the Bill and Melinda Gates Foundation, it has grown into an international consortium of more 
than 3,600 researchers, with more than 200 papers published. GBD estimates are now 
arguably the most well-known, well-used and well-cited burden of disease estimates, and 
have had a profound impact on health policy and agenda-setting throughout the world, 
especially as it has brought global attention to otherwise hidden or neglected diseases and 
injuries.(19-23)  
While estimates have been presented for diabetes mellitus in GBD capstone papers, the 
estimates for the disabling sequelae that make up the diabetes mellitus burden have not been 
described in detail, including DRLECs.(19) Although it is apparent in these capstone papers 
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that the global burden of diabetes is comparatively large and has markedly increased over 
recent decades,(19) and it could be expected that the disease burden of DRLECs would have 
a commensurate increase, to date, global, regional and national estimates and changes over 
time related to DRLECs remain hidden. Thus, this paper uses GBD data with the primary aim 
to provide global prevalence and disability burden (YLDs) estimates for individual and overall 
DRLECs in 2016. Secondary aims are to further explore these 2016 estimates by sex, age, 21 
regions, and 195 countries or territories, and over time compared to 1990 estimates. Such 
estimates should enable health service providers and researchers to evaluate the 
comparative disease burden DRLECs have on their population of interest, and in turn inform 
decisions about resource allocation to target cost-effective prevention and treatment at 
populations disproportionately affected. 
 
Research Design and Methods 
Research design 
This study was a secondary analysis of GBD 2016 data obtained from the Institute for Health 
Metrics and Evaluation (IHME), Seattle, USA. IHME provided prevalence and YLD estimates 
for diabetes mellitus and DRLEC-related sequelae by sex, 20 age groups, 21 regions and 195 
countries or territories, for the years 2016 and 1990. Prevalence and YLDs were provided in 
counts, rates and age-standardized rates, with 95% uncertainty intervals (UI). Results of this 
study were reported according to the Guidelines for Accurate and Transparent Health 





Since 1990, GBD has been estimating global disease burden by quantifying the health loss 
from premature mortality and non-fatal disability.(19-23) GBD attributes the health loss to 
hundreds of causes (diseases and injuries that cause death or disability) which are made up 
of thousands of sequelae (complications of those causes) using a mutually-exclusive and 
exhaustive list of causes organised into a hierarchy of levels.(19) Level 1 causes consist of 
three broad overarching cause groups, such as Non-communicable diseases.(19) These are 
disaggregated into >20 Level 2 cause groups, such as Diabetes, urogenital, blood and 
endocrine diseases.(19) These are further disaggregated into >100 Level 3 causes, such as 
Diabetes mellitus, and again into >200 Level 4 causes, such as Chronic kidney disease (CKD) 
due to diabetes mellitus.(19) Finally, these Level 4 causes are disaggregated into >2,000 
sequelae, such as the DRLEC-related sequelae of Diabetic neuropathy and amputation with 
treatment.(19) Thus, the prevalence and YLD estimates for all the sequelae of a particular 
Level 4 cause should sum exactly to the prevalence and YLD estimate of that Level 4 cause, 
respectively, and so on up the hierarchy of levels. 
GBD is now remeasured and republished at least every three years. For each new iteration, 
GBD provides new estimates not only for more recent years, but also for all previous years as 
improvements in GBD methodology are implemented. These new estimates for previous 
years supersede any previously published result estimates for those years, including 1990 
estimates. GBD 2016 estimated global prevalence, incidence, and YLDs for 328 causes and 
2982 sequelae, for 21 regions, and 195 countries or territories during 1990-2016.(19, 25) The 
extensive GBD 2016 methodology has been published in detail elsewhere.(19, 25) For the 
purpose of this paper, we summarise the methodology used in the prevalence and YLD 
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estimations for diabetes mellitus and its eight mutually exclusive sequelae: uncomplicated 
diabetes mellitus, moderate vision loss due to diabetes mellitus, severe vision loss due to 
diabetes mellitus, blindness due to diabetes mellitus, diabetic neuropathy, diabetic foot due 
to neuropathy, diabetic neuropathy and amputation with treatment, and diabetic neuropathy 
and amputation without treatment.(19) 
 
Case Definitions  
As a cause in GBD 2016, Diabetes mellitus was defined as those with a fasting plasma glucose 
(FPG) > 126 mg/dL (7 mmol/L) or being on treatment for diabetes.(19) DRLECs were defined 
as the four mutually exclusive DRLEC-related sequelae of Diabetes mellitus: 1. Diabetic 
neuropathy, defined as cases of diabetes mellitus with diagnosed neuropathy that do not 
currently have a foot ulcer or previous major amputation;(19) 2. Diabetic foot due to 
neuropathy, cases of diabetes mellitus that currently have a foot ulcer;(19) 3. Diabetic 
neuropathy and amputation without treatment, cases of diabetes mellitus that have 
previously had major leg amputation(s) (above or below the knee) that do not have a 
prosthetic limb to ambulate (and instead require crutches or similar aide to move around); 4. 
Diabetic neuropathy and amputation with treatment, cases that have previously had major 
leg amputation(s) (above or below the knee) that do have a prosthetic limb to ambulate.(19) 
Amputation was broken down into with and without treatment (i.e. with and without 
prosthesis) to more accurately estimate disability burden, based on studies that those with 
major amputation without a prosthesis had markedly worse quality of life and disability 
burdens than those with a prosthesis.(19, 26-28) Cases with multiple DRLEC-related sequelae 
were assigned the most severe of their DRLECs as their only DRLEC so as to be counted only 
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once. Full case definitions and diagnostic criteria with associated ICD 9 and ICD 10 codes are 
presented in eTable 2. Shortened terms are used to denote these four sequelae for the 
remainder of this paper as neuropathy, foot ulcer, amputation with prosthesis, and 
amputation without prosthesis, respectively.  
 
Prevalence estimation 
In GBD, prevalence was estimated firstly for causes, and then split into sequelae. For all 
included causes, GBD initially performed systematic reviews to identify all available data 
sources from published articles and unpublished registry data prior to December 31, 2016.(19) 
All accessible information identified on disease occurrence, natural history, and any sequelae 
based on severity for a cause such as diabetes, then passed a strict set of inclusion criteria 
and adjustments, to maximise the comparability of the data, despite if different collection 
methods or case definitions were used in the included studies over time. For diabetes, data 
from 806 prevalence articles were extracted and processed, including time, age and sex 
splitting. A series of adjustments were then made if required, this involved crosswalking data 
inputs from studies with less desirable methods to data inputs from optimally conducted 
studies. Crosswalks between several different case definitions with different thresholds of 
FPG or glycated hemoglobin levels for diabetes mellitus were used based on available data 
with individual records of the actual measurements. The adjusted input data were entered 
into a validated Bayesian meta-regression tool DisMod-MR 2.1 to produce adjusted pooled 
prevalence estimates for diabetes for each age-sex-country-year combination.(19) To predict 
estimates for countries with sparse or no available data, GBD uses a ‘wrapper’ code that bases 
country estimates on the regional estimates from the geographical parent region for that 
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country. Furthermore, in the case of countries with no data, the coefficients for the parent 
geographical region were also used to take advantage of the predictive power of the 
covariates in a meta-regression. In the case of diabetes, a range of covariates were 
systematically tested, and two covariates were chosen to further inform estimates for data-
sparse countries based on statistical fit (AIC and adjusted R2): prevalence of obesity per 
country and lag-distributed income per capita.(19)  
 
For DRLEC-related sequelae, GBD included 89 prevalence articles for neuropathy, 43 for foot 
ulcer and 12 for amputation. Separate DisMod-MR 2.1 models were used to produce pooled 
estimates of the proportion of diabetes population affected by each different sequela. These 
proportion estimates were multiplied by the estimated prevalence of diabetes to determine 
prevalence estimates for each sequela after a series of adjustments.(19) Crosswalks were 
again performed to adjust for any studies using different DRLEC diagnostic criteria to that 
used as the case definition by GBD for each DRLEC (see eTable 2). A series of “squeeze” 
adjustments were then made to ensure firstly that the sum of all complicated sequelae did 
not exceed 90% of the diabetes prevalence, and secondly that the sum of foot ulcer and 
amputation did not exceed 90% of the total neuropathy prevalence.(19) Finally, the 
amputation prevalence was split into those with and without prosthesis, based on a 
standardised scaled country-specific health system access covariate developed by GBD and 
the assumption that at least 10% of amputees will not receive a prosthetic, supported by data 
from a pivotal historical study reporting the proportion of prosthetic treatment for major 
amputations(26) and since supported by multiple contemporary studies.(29-31) A 
population-weighted average was then performed to obtain a regional estimate for the 
proportion of amputees that receive a prosthetic.  This adjusted regional proportion was then 
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used as the proportion of amputation with prosthesis for each country and a conservative 
confidence interval of ±50% applied to adjust for any uncertainty of these prosthesis 
proportion assumptions.(19)  
 
Adjusted prevalence estimates were then produced using DisMod-MR 2.1 for each DRLEC-
related sequelae for each age-sex-country-year combination, based on the GBD reference 
population, a standard global reference population structure used to facilitate such age-
standardised rate comparisons.(32, 33) For countries with sparse or no DRLEC data the 
aforementioned wrapper code was again used to adjust estimates based on the estimates of 
geographical parent region. All GBD 2016 estimates have been estimated with uncertainty. 
Uncertainty comes from many sources, including heterogeneity in the empirical data that are 
available and identified through systematic reviews, and uncertainty in the indirect 
estimation models used to make predictions for populations with little or no data. Because 
the empirical basis for estimating prevalence is much weaker for some DRLECs sequelae than 
for others, uncertainty varies substantially between sequelae, and within sequelae across 
regions and countries. 
 
Years lived with disability (YLDs) estimation 
The disability burden resulting from a sequela or cause within a population is measured using 
YLDs.(19) YLDs are calculated by multiplying the prevalence estimate of a sequela by a 
disability weight for the same sequela.(19) The disability weight represents the average 
severity of non-fatal health loss associated with the particular sequela on a scale of 0 
(equivalent to perfect health) to 1 (equivalent to death).(19, 34) For example, uncomplicated 
diabetes has a comparatively low disability weight of 0.049, whereas, blindness due to 
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diabetes has a comparatively high disability weight of 0.187.(19) Disability weights were 
determined from a series of multinational, household-based or web-based surveys, “which 
used paired comparison questions in which respondents considered two hypothetical 
individuals with different health states and specified which person they deemed 
healthier”.(34) Data from these surveys were analysed and rescaled to disability weight units 
between 0 and 1.(34) Lay descriptions of the four DRLEC-related sequelae used to frame the 
comparison questions can be found in eTable 2. The final stage in the estimation of YLDs is a 
micro-simulation that adjusts for comorbidity. It is performed by simulating 40,000 individuals 
for each age-sex-country-year. Based on the prevalence estimates of sequelae, these 
simulated individuals end up having none to multiple disease sequelae. The disability weight 
for each individual is estimated based on the sequelae they acquired and the disability weight 
is then attributed to each sequela. The disability weight determined for neuropathy was 0.133 
(0.089–0.187).(19) The disability weights for the other three sequelae were calculated as a 
combination of two health states: neuropathy and foot ulcer (0.02 (0.01‐0.034)) or 
amputation with prosthesis (0.039 (0.023 – 0.059)), or amputation without prosthesis (0.173 
(0.118 – 0.24)). (19)  
 
Analysis 
We transformed all data provided by IHME into tables and figures to display the global 
prevalence and YLDs of individual and overall DRLECs in 2016 and 1990, and the composition 
by sex, 20 age groups, 21 regions, and 195 countries or territories. Prevalence and YLDs were 
presented in counts, all-age rates and age-standardized rates, with 95% uncertainty intervals 
(UI). Overall DRLEC prevalence and YLDs were calculated by summing mean estimates of the 
four DRLECs-related sequelae. Mean percentage changes between 1990 and 2016 were 
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calculated for all outcomes in counts, all-age rates, and age-standardized rates. Change in 
counts reflects the combined effects of population growth, population ageing, and 
epidemiological change.(19) Population ageing and epidemiological change explain the mean 
percentage change in all-age rates, while the change in age-standardised rates reflects 
epidemiological change that is not due to ageing or population growth.(19) Male-to-female 
ratios were also calculated across age groups. Estimates were considered significantly 




Tables 1 displays global prevalence and YLD estimates for diabetes, individual and overall 
DRLECs in 2016, and percentage changes from 1990 to 2016. In 2016, there were an estimated 
131.0 million people (1.77% of the global population) affected by overall DRLECs, including 
105.6 million (95% UI, 85.5 to 128) with neuropathy only, 18.6 million (15.0 to 22.9) with foot 
ulcers, 4.3 million (3.7 to 4.9) amputation without prosthesis, and 2.5 million (2.1 to 3.0) 
amputation with prosthesis. The age-standardized prevalence rates showed that 1,848 per 
100,000 were affected, including 1,480 (1,201 to 1,783) with neuropathy only, 270 (217 to 
332) foot ulcers, 60.6 (52.6 to 69.2) amputation without prosthesis, and 36.7 (30.2 to 43.9) 
amputation with prosthesis. 
An estimated 16.8 million YLDs (2.07% of global YLDs) were caused by DRLECs in 2016, 
including 12.9 million (8.30 to 18.8) from neuropathy only, 2.5 million (1.7 to 3.6) from foot 
ulcers, 1.1 million (0.7 to 1.4) from amputation without prosthesis, and 0.4 million (0.3 to 0.5) 
from amputation with prosthesis. The age-standardized YLD rates for DRLECs was 237 per 
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100,000, including 180 (116 to 263) from neuropathy only, 36.3 (23.8 to 51.4) foot ulcers, 15.1 
(10.6 to 20.4) amputation without prosthesis, and 5.4 (3.6 to 7.6) amputation with prosthesis. 
Compared to 1990 estimates, counts of prevalence and YLDs in 2016 increased significantly 
by between 110.4% (neuropathy) and 140.3% (amputation without prosthesis). Age-
standardised rates of prevalence and YLD also increased by between 14.9% (neuropathy) and 
31.5% (amputation without prosthesis) from 1990 to 2016, though statistical significance of 
these increases is unclear due to overlapping 95% UIs.  
Insert Table 1  
 
Sex & age findings 
Figure 1 shows sex and age composition in YLD counts (A) and rates (B) in 1990 and 2016. In 
2016, male-to-female ratios for age-standardised YLD rates were 1.11 for overall DRLECs, 0.96 
for neuropathy, 1.56 for amputations (both with and without prosthesis) and 1.93 for foot 
ulcers. See eTable 3 for male-to-female ratios for YLD counts and rates in each age group. Age 
groups accounting for most YLD counts of individual DRLECs were: neuropathy, 50-54 years 
in males and 55-59 years in females; foot ulcers, 60-64 years in both sexes; amputation 
without prosthesis, 60-64 years in both; and amputation with prosthesis, 65-69 years in both 
(eTable 3). In summary, the 50-69 years-old accounted for most (47.8%) of the overall DRLEC 
YLD counts in 2016, while people aged >70 years had higher YLD rates. YLD rates in 2016 
increased in nearly all age groups compared to 1990 (eTable 3).  





Figure 2 shows broad variation in age-standardised YLD rates across the 21 regions in 1990 
and 2016. In both 1990 and 2016, highest YLD rates of overall DRLECs were in North Africa 
and Middle East, Central Latin America, Oceania and Caribbean, whilst lowest rates were in 
East Asia, Western Sub-Saharan Africa, Australasia and Western Europe. The largest increases 
from 1990 to 2016 were in Southern Sub-Saharan Africa, South Asia and Southeast Asia, 
whereas a decrease was only observed in High-income Asia Pacific region .  
 
For individual DRLECs in 2016, highest YLD rates of neuropathy were in North Africa and 
Middle East (493.9, 318.9 to 726.2 per 100,000), of foot ulcers in Oceania (103.8, 68.6 to 
147.9), amputation without prosthesis in Southern Sub-Saharan Africa (44.4, 30.1 to 59.7), 
and with prosthesis in High-income North America (20.3, 12.3 to 28.8). Figure 3 displays world 
maps of age-standardised YLD rates for overall DRLECs across 195 countries or territories in 
1990(A) and 2016(B). The country with the highest overall DRLECs rate was the Marshall 
Islands (1096.4 per 100,000), while the lowest was Switzerland (97.1). World maps for 
prevalence and YLDs of individual DRLECs can be found in eFigure1 and 2, with specific data 
presented in eTable 5 and 6. 
Insert Figure 2 and Figure 3 here 
 
DISCUSSION 
We have presented detailed estimates on the disability burden caused by DRLECs for the first 
time. Based on GBD 2016 data, an estimated 131.0 million (1.77%) people worldwide had 
DRLECs in 2016, including 105.6 million with neuropathy only, 18.6 million with foot ulcers 
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and 6.8 million with amputations (with or without prosthesis). This resulted in 16.8 million 
YLDs (2.07% of all YLDs), including 12.9 million from neuropathy only, 2.5 million from foot 
ulcers and 1.6 million from amputations. Overall, the DRLEC disability burden appeared to 
disproportionately affect males, 50-69 year aged groups and those living in the regions of 
North Africa and Middle East, Central Latin America, Oceania and Caribbean. Compared to 
1990 estimates, the 2016 global estimates for age-standardized YLD rates increased by 16.7% 
for overall DRLECs, and for individual DRLECs the increases ranged from 14.9% for neuropathy 
to 31.5% for amputation without prosthesis. Regional changes in age-standardized YLD rates 
of overall DRLECs also varied over time for different regions, from 45.4% increase in Southern 
Sub-Saharan Africa to 11.6% decrease in High-income Asia Pacific. 
 
To our knowledge our previous brief letter was the first to highlight the contribution of 
DRLECs to the global burden of disability. In this paper, we report an estimated 16.8 million 
YLDs resulted from DRLECs based on GBD 2016 data, a lower estimate than the 20.5 million 
in 2015 based on GBD 2015 data in the previous letter.(18) This apparent decrease is most 
likely explained by lower prevalence estimates of diabetes and DRLECs in GBD 2016: estimates 
decreased from 435 million(35) in 2015 to 383 million(19) in 2016 for diabetes prevalence, 
which resulted an decrease from 159 million(18) to 131 million for DRLECs. Unlike previous 
GBD estimates,(35) GBD 2016 excluded all articles using self-reported diabetes diagnosis 
which are known to overestimate prevalence of diabetes.(19) Thus, the remeasured GBD 
2016 estimates reported in this paper, for the new estimation year 2016 and for the previous 
year 1990 using new data from annual updates, improved case definitions and modelling, 




As YLDs are a product of prevalence and disability weight, and disability weight has remained 
the same, it is also reassuring that our prevalence estimates appear to be similar to those 
reported in the very few other previous papers.(5, 6, 16) We report 131 million people with 
diabetes had DRLECs, i.e. neuropathy either alone or with foot ulcers or amputations, 
equalling 34% of diabetes population. Somewhat reassuringly our 34% finding seems to 
plausibly fit within the neuropathy range, reported in a recent review, of 10%-15% in newly 
diagnosed diabetes patients and up to 50% in those with >10 year diabetes duration.(6) 
Additionally, we report an estimated 18.6 million (4.8%) people with diabetes have a foot 
ulcer which aligns very closely with a 4.6% global pooled prevalence estimated in a meta-
analysis.(16) Although studies have investigated diabetes-related major amputations, as per 
the combined definition of our amputation outcomes (with or without prosthesis), they did 
so using incidence and thus we are unable to compare our prevalence findings for 
amputations.(17)  
 
Our estimate of 16.8 million YLDs from DRLECs equates to 59% of the diabetes YLDs (28.6 
million). Interestingly, when compared to all 271 Level 4 causes in GBD 2016, in terms of the 
proportion of overall YLDs (805.4 million) by each cause, diabetes mellitus (3.54%) was the 8th 
leading cause, made up of DRLECs (2.07%), diabetes-related vision loss (0.03%) and 
uncomplicated diabetes (1.43%).(19) If we further compare DRLECs (2.07%) with all Level 4 
causes, DRLECs would rank between the 10th leading cause (falls: 2.35%) and the 11th leading 
cause (chronic obstructive pulmonary disease: 2.06%).(19) Furthermore, DRLECs would rank 
as having a higher global disability burden than ischemic stroke (17th; 1.47%), ischemic heart 
disease (29th; 0.86%) and CKD due to diabetes (52nd; 0.46%) which is listed in GBD as a 
separate cause rather than a sequela of diabetes (eTable 4).(19) Thus, our estimate indicates 
17 
 
that DRLECs make up a very large proportion of the diabetes disability burden, and a 
comparatively large proportion of the overall global disability burden in 2016. In an ageing 
global population, diseases largely affecting the elderly such as diabetes will become more 
prominent causes of YLDs. The increase in diabetes and the improved survival in people with 
diabetes through prevention of deaths from cardiovascular complications will most likely lead 
to further increases in prevalence and a need to prevent these disabling complications of 
diabetes, in particular DRLECs. 
 
This comparatively large disability burden of DRLECs appeared to disproportionately affect 
males, and the largest proportion (47.8%) of this burden affected 50-69 years-old population. 
These are not unique findings as diabetic foot ulcers and amputations have consistently been 
reported to be much higher in the male population, with median ages of disease onset in this 
same middle-to-older aged bracket.(16, 36, 37) The previous meta-analysis on diabetic foot 
ulcer prevalence reported a male-to-female ratio equating to 1.3.(16) While, a recent 
systematic review on diabetic amputation incidence reported a male-to-female ratio range 
between 1.5 to 3.0,(36, 37) and attributed this to males having a higher prevalence of smoking, 
peripheral neuropathy, peripheral artery disease and foot ulceration.(36) We did not find this 
for neuropathy, although neuropathy did appear to affect males more so in middle-aged 
groups than females,(38) but did for foot ulceration. Similarly, increasing proportions of 
diabetes-related complications have been reported in the middle-aged populations. A recent 
review identified that the proportional contribution of 45-64 year olds to all diabetes-related 
strokes increased from 20.1% to 31.4% and amputation from 32.4% to 52.8% during 1990 and 
2010.(3) It could be suggested that the large proportional contribution of middle-aged groups 
may partly be attributed to the relatively large size of middle-aged groups compared with 
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other age groups, as suggested by the changing shapes of counts and rates over time in figure 
1. 
 
Our findings also showed that almost all regions were faced with increased burden of DRLECs. 
Along with the global epidemic of diabetes and interventions to prevent death and prolong 
life, more people were living with diabetes, and this increasingly complicated population are 
placing extra challenge on health systems worldwide. The most affected regions found in this 
study were North Africa and Middle East, Central Latin America and Oceania, perhaps not 
surprisingly, as these were the same regions most affected by diabetes,(19) however 
inadequate healthcare provision might be another underlying factor. An attempt to evaluate 
healthcare system performance in GBD is via a ratio of actual disease burden to expected 
disease burden. If the ratio is larger than one (actual burden exceeds expected burden), it is 
suggested that healthcare systems in those geographical locations are not performing to 
levels necessary to cope with the specific disease.(19) In both Central Latin America and 
Oceania, actual YLDs from diabetes significantly outnumbered the expected by two-fold, 
indicating that the quality of local healthcare are not meeting the needs of their diabetes 
population.(19) Another attempt GBD has made to assess healthcare is via the establishment 
of Health Access Quality index which assesses personal healthcare access and quality for 
regions and countries.(39) GBD reports that Oceania scored 36.0 out of 100 possible total 
score. Though North Africa and Middle East scored a higher 55.8, large between-country 
variation exists, ranging from Afghanistan (25.9) to Lebanon (85.6).(39) Interestingly, only 
High-income Asia-Pacific (Japan, South Korea, Singapore and Brunei) saw reductions in 
disability burden from almost every DRLEC since 1990. Perhaps researchers could investigate 
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the strategies employed in this region that may have led to their apparent DRLEC success, and 
in turn employ in those regions most affected.  
 
Several limitations should be taken into consideration when interpreting these findings. First, 
our estimates for diabetic neuropathy may be an over-estimate. Unlike the other three 
outcomes, neuropathy can affect more than just lower extremities. Whilst, the GBD definition 
of diabetic neuropathy included only peripheral neuropathy, this does mean that upper as 
well as lower extremities were included. However, peripheral neuropathy is known to 
overwhelmingly affect lower extremities so any over-estimate should be minimal.(6) 
Conversely, if we chose to exclude neuropathy it would have resulted in a significant 
underestimate of the overall burden.(4, 5) Second, we did not have data to include other 
diabetic complications of the lower extremity that also cause significant disability, such as 
peripheral artery disease, foot infections and minor amputations.(4, 5) Thus, our overall 
DRLEC burden may in fact be an under-estimate of the actual overall DRLECs, and there’s a 
need to improve the way DRLECs are captured and categorized in future GBD iterations so 
that the overall DRLEC burdens are more comprehensively estimated. Third, we were reliant 
on GBD data, and caution is needed when interpreting the results, particularly in data-sparse 
countries with wide 95% UI around estimates. While there has been significant investment in 
improving GBD global disease modelling approaches, there is still a need for more investment 
to improve vital registration and data in developing countries. The accuracy of DRLECs 
estimates depend on the availability of reliable and comparable information, and as better-
quality evidence becomes available, future disease modelling at a global level will be more 
accurate and reliable. Fourth, disability weights, a crucial component of YLDs, were derived 
from models using survey data, and responses from these surveys were sensitive to details 
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included in the lay descriptions.(34) Further improvements on disability weight methodology 
may also improve the precision of estimates in future. Fifth, some results, including the overall 
DRLEC prevalence and YLDs estimates were a simple summation of individual DRLECs by the 
authors, and 95%UI for these findings were not estimated. Last, diabetes is also associated 
with increased risk of mortality, however given the complex inter-relationships between 
diabetes complications and other comorbidities causing mortality, estimating the impact of 
individual complications on mortality remains challenging, hence we were unable to 
investigate the mortality burden of DRLECs. 
 
Despite these limitations, results from this study adds significant novel knowledge on the 
global burden of DRLECs. DRLECs appear to be a large contributor to the global disability 
burden, and this age-standardized burden has increased by 15-31% since 1990. Disability from 
DRLECs appeared to disproportionately affect males, the middle-to-older aged groups, and 
specific regions. It is recommended that these populations are targeted by DRLEC strategies 
shown to reduce these burdens. Whilst general diabetes management strategies may help to 
reduce the DRLEC disability burden via prevention of complications, evidence suggest that 
the most significant DRLEC burden reductions were from DRLEC-specific strategies, such as 
the introduction of interdisciplinary foot care services adhering to evidence-based 
guidelines.(4, 5, 11) Thus, in a similar manner to how CKD due to diabetes mellitus is treated 
as a separate cause by GBD and others, we also recommend that DRLECs should be monitored 
and addressed separately. This would allow ongoing interpretations of DRLECs and will 
particularly facilitate worldwide policy makers and clinicians to tackle DRLECs, a leading cause 
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Table 1 Global prevalence, years lived with disability (YLDs) in 2016, and percentage change from 1990 to 2016, of diabetes and diabetes-related lower extremity 
complications (DRLECs)  



















130,951,860                                
rates 
5.187% (4.769 to 5.608) 1.428% (1.157 to 1.730) 
0.251% (0.203 to 
0.310) 
0.058% (0.050 to 
0.066) 




5334.8 (4908.6 to 5759.7) 
1479.8 (1200.7 to 
1782.6) 
269.7 (217.1 to 331.6) 60.6 (52.6 to 69.2) 36.7 (30.2 to 43.9) 1848.0 
       
Mean change in prevalence from 1990 to 
2016^ 
     
of counts 112.6% 110.4% 129.8% 140.7% 116.3% 114.0% 
of rates 51.4% 49.0% 63.2% 71.7% 53.5% 63.0% 
of ASR 19.5% 14.6% 20.5% 31.0% 15.4% 15.9% 
       
YLDs in 2016       
counts 28,583,685 (19,533,803 to 
39,574,719) 




1,066,553 (753,179 to 
1,436,595) 




3.51% (3.05 to 4.05) 1.582% (1.019 to 2.314) 
0.308% (0.203 to 
0.437) 
0.131% (0.092 to 
0.176) 
0.047% (0.031 to 
0.065) 
2.068% 
ASR  398.8 (273.6 to 550.9) 179.9 (115.9 to 262.7) 36.3 (23.8 to 51.4) 15.1 (10.6 to 20.4) 5.4 (3.6 to 7.6) 236.7 
       
Mean change in YLDs from 1990 to 2016^      
of counts 113.7% 110.4% 129.7% 140.3% 115.8% 114.9% 
of proportion 41.0% 49.8% 63.3% 71.1% 53.4% 53.0% 
of ASR 18.8% 14.9% 20.6% 31.5% 15.8% 16.7% 
ASR, age-standardized rate.  
Prevalence and YLDs of diabetes, neuropathy, foot ulcer, amputation without prosthesis, and amputation with prosthesis are presented as mean (95% uncertainty intervals) in counts, rate/proportion and age-
standardized rate (ASR) was presented; mean estimates were presented for overall DRLECs. Rates and age-standardized rates were calculated based on the GBD 2016 reference population.(19),(32)  
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*Proportion means the proportion of overall global YLDs from all causes in the corresponding year. Overall global YLDs are 532,835,179 in 1990 and 805,393,000 in 2016, and are sourced from GBD Compare Viz Hub 
(https://gbd2016.healthdata.org/gbd-compare/) 




Figure 1: Sex and age composition of global YLD counts (A) and rates (B) for diabetes-related lower extremity 
complications (DRLECs) in 1990 and 2016. 
Figure 2: Regional YLD rates (age-standardized, per 100,000) of diabetes-related lower extremity complications 
(DRLECs) in 1990 ,2016, and percentage change from 1990 to 2019. 
Legend: *% change is for the region denoted in 2016. 
Figure 3: World map of age-standardized YLD rates (per 100,000) for overall diabetes-related lower extremity 
complications (DRLECs) in 1990(A) and 2016(B)  
 
